Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 3Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 11Leukemia, Myeloid, Acute 5Uveal Melanoma 4Prostatic Neoplasms 4Myelodysplastic Syndromes 4Uterine Cervical Neoplasms 3Sarcoma 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Gastrointestinal Stromal Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Gliosarcoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Doxorubicin 13Ifosfamide 10Radiotherapy 6Sunitinib 3pegfilgrastim 2Trabectedin 2Radiotherapy, Conformal 2Nivolumab 2Methotrexate 2Ipilimumab 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Cisplatin 2Chemotherapy, Adjuvant 2tremelimumab 1temsirolimus 1soblidotin 1saracatinib 1romidepsin 1ribociclib 1reolysin 1perifosine 1pembrolizumab 1pazopanib 1olaratumab 1montanide ISA 51 1liposomal doxorubicin 1indolepropanol phosphate 1exatecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Histiocytoma, Malignant Fibrous × CTLA-4 Antigen × Clear all
NCT02500797 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
164 enrolled 22 charts
Sarcoma

Bone Neoplasms, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡